Abstract: The invention relates to the monoclonal antibody 1G2, the hybridoma cell line H-1 G2 characterized by DSM ACC3248, and the epitope TPP comprising the amino acids threonine, proline, proline. The invention further relates to a method for producing a monoclonal antibody against a TAU protein fraction that is non-phosphorylated in positions T175 and/or T181 and/or T231. The invention also describes uses of the monoclonal antibody 1 G2 as well as an immunochemical detection system and the uses thereof. The invention finally describes the use of the immunochemical detection system for diagnosing Alzheimer's disease in humans.

Abstract: The invention relates to the monoclonal antibody 1G2, the hybridoma cell line H-1 G2 characterized by DSM ACC3248, and the epitope TPP comprising the amino acids tryptophan, proline, proline. The invention further relates to a method for producing a monoclonal antibody against a TAU protein fraction that is non-phosphorylated in positions T175 and/or T181 and/or T231. The invention also describes uses of the monoclonal antibody 1 G2 as well as an immunochemical detection system and the uses thereof. The invention finally describes the use of the immunochemical detection system for diagnosing Alzheimer's disease in humans.

Abstract: A method of using at least one quantitative ratio of two different amyloid beta-peptides in a sample of a body fluid from a patient for determining the patient's probability of contracting Alzheimer's disease (AD) or for determining the patient's suffering from a precursor of Alzheimer's disease includes obtaining the sample of the body fluid from the patient. The at least one quantitative ratio is calculated from the two different amyloid beta-peptides from the sample. The patient's probability of contracting Alzheimer's disease (AD) or the patient's suffering from a precursor of Alzheimer's disease is calculated using the at least one quantitative ratio. The two different amyloid beta-peptides are selected from (a) A?(1-42), (b) A?(2-40) and (c) A?(2-42). The at least one quantitative ratio is selected from (a) A?(1-42)/(b) A?(2-40), (a) A?(1-42)/(c) A?(2-42), (b) A?(2-40)/(a) A?(1-42) and (c) A?(2-42)/(a) A?(1-42).

Abstract: In an ex vivo method of differentially diagnosing dementias selected from a group of demetias, which includes vascular dementias and frontotemporal lobe degenerations, a concentration of at least one carboxy-terminally truncated amyloid ? peptide species as a biomarker is determined in a body fluid obtained from a patient, the at least one carboxy-terminally truncated amyloid ? peptide species being selected from the group of species consisting of A?1-38, A?1-37 and A?1-39; and the concentration of the at least one carboxy-terminally truncated amyloid ? peptide species is compared to a threshold concentration value for the respective one carboxy-terminally truncated amyloid ? peptide species.

Abstract: A method of diagnosis of Alzheimer's disease comprising the steps of obtaining a sample selected from of a group of samples consisting of body fluid samples and tissue homogenate samples from a patient; of exposing the sample to an antibody directed against Amyloid-beta (A?) peptides; of separating a fraction of the sample bond to the antibody from a remainder of the sample not bond to the antibody; and of determining an amount of at least one species selected from a group of species consisting of species having molecular masses in a range of 3870 to 3895 Da, 4520 to 4545 Da, 4802 to 4836 Da, 4837 to 4871 Da, and 7720 to 7790 Da in the fraction of the sample bond to the antibody.